Publikationen - Auswahl der letzten 5 Jahre Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H,
Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P;
Gastroenterology. 2010 Feb;138(2):503-12, 512.e1. Epub 2009 Nov 10
Germline mutation of the E-cadherin gene in three sibling cases with advanced gastric cancer: clinical consequences for the other family members.
Mayrbaeurl B, Keller G, Schauer W, Burgstaller S, Czompo M, Hoebling W, Knoflach P, Duba HC,
Eur J Gastroenterol Hepatol. 2010 Mar;22(3):306-10.
Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology
Reinisch W, Haas T, Kaser A, Petritsch W, Vogelsang H, Feichtenschlager T, Novacek G, Siebert
Z Gastroenterol. 2009 Apr;47(4):372-80. Epub 2009 Apr 8. German.
Quantitative autonomic testing in the management of botulism.
Topakian R, Heibl C, Stieglbauer K, Dreer B, Nagl M, Knoflach P, Aichner FT.
J Neurol. 2009 May;256(5):803-9. Epub 2009 Feb 25.
Concomitant manifestation of pyoderma gangrenosum and colorectal carcinoma.
Bunte C, Popp-Habeler J, Mischer P, Tuppy H, Haidenthaler A, Knoflach P, Kirchgatterer A.
Scand J Gastroenterol. 2008;43(6):756-8.
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M,
Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis
Gastroenterology. 2008 Aug;135(2):451-8. Epub 2008 May 27.
The frequency of wound infections after PEG-placement and utilization of glycogel wound dressing: a randomized controlled trial
Aschl G, Kirchgatterer A, Fleischer M, Hinterreiter M, Hubner D, Kranewitter W, Stadler B,
Wien Klin Wochenschr. 2008;120(7-8):224-7. German
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof
M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K; Austrian Hepatitis
Variceal hemorrhage in a patient with ulcerative colitis treated with 6-Thioguanine.
Inflamm Bowel Dis. 2008 Apr;14(4):582-3.
A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.
Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J,
Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth
Wien Klin Wochenschr. 2007;119(17-18):519-26.
Use of infliximab in ulcerative colitis
Tilg H, Feichtenschlager T, Knoflach P, Petritsch W, Schöfl R, Vogelsang H, Reinisch W.
Z Gastroenterol. 2007 Aug;45(8):907-11. German
Long-term outcome following placement of percutaneous endoscopic gastrostomy in younger and older patients.
Kirchgatterer A, Bunte C, Aschl G, Fritz E, Hubner D, Kranewitter W, Fleischer M, Hinterreiter M,
Scand J Gastroenterol. 2007 Feb;42(2):271-6.
ERCP is safe and effective in patients 80 years of age and older compared with younger patients.
Fritz E, Kirchgatterer A, Hubner D, Aschl G, Hinterreiter M, Stadler B, Knoflach P.
Gastrointest Endosc. 2006 Dec;64(6):899-905.
Endoscopy in IBD. A Consensus Report of the IBD Working of the Austrian Association of Gastroenterology and Hepatology
Petritsch W, Tillinger W, Vogelsang H, Reinisch W, Knoflach P, Tilg H.
Z Gastroenterol. 2006 Nov;44(11):1183-92. German
Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases-- consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the
Dejaco C, Haas T, Kirchgatterer A, Miehsler W, Wenzl H, Knoflach P, Petritsch W, Vogelsang H,
Z Gastroenterol. 2006 Jun;44(6):525-38; discussion 539. Review. German.
6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
de Boer NK, Reinisch W, Teml A, van Bodegraven AA, Schwab M, Lukas M, Ochsenkühn T,
Petritsch W, Knoflach P, Almer S, van der Merwe SW, Herrlinger KR, Seiderer J, Vogelsang H,
Digestion. 2006;73(1):25-31. Epub 2006 Feb 21. Review.
Weight loss, abdominal pain and anemia after a holiday abroad--case report of lead poisoning
Dtsch Med Wochenschr. 2005 Oct 7;130(40):2253-6. German.
Lansoprazole-associated collagenous colitis: a case report.
Rammer M, Kirchgatterer A, Höbling W, Knoflach P.
Contacts: Forest Laboratories, Inc. ChemoCentryx, Inc. For media inquiries Partners Karen L. Bergman 650.575.1509 or Michelle Corral 415.794.8662 CHEMOCENTRYX AND FOREST LABORATORIES TO COLLABORATE ON THE DEVELOPMENT AND COMMERCIALIZATION OF NOVEL ORAL RHEUMATOID ARTHRITIS AND MULTIPLE SCLEROSIS THERAPEUTICS March 15, 2004; San Carlos, CA and New York, NY �